SOYACAL 10% (soybean oil) by HBM Alpha Therapeutics is patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. First approved in 1983.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
SOYACAL 10% is a soybean oil-based parenteral nutrition product administered intravenously to provide macronutrients and micronutrients. It delivers amino acids, dextrose, and lipids that support protein synthesis, energy production, and essential fatty acid supply. The product is indicated for patients requiring nutritional support when oral or enteral intake is insufficient or unavailable.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), suggesting declining market opportunity and smaller commercial team investment.
patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Soybean Oil Trial of cArdiovascular Risk
Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Worked on SOYACAL 10% at HBM Alpha Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Career prospects on SOYACAL 10% are limited, with zero linked job openings and a product in LOE phase under commodity competitive pressure. Professionals joining this team would focus on generic transition planning, manufacturing compliance, and cost optimization rather than growth or innovation.